Lifeward (LFWD) to Release Quarterly Earnings on Friday

Lifeward (NASDAQ:LFWD) is projected to issue its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $7.8680 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Lifeward Stock Performance

Shares of Lifeward stock opened at $5.99 on Thursday. The company has a market capitalization of $9.10 million, a PE ratio of -0.17 and a beta of 0.12. The company has a 50-day simple moving average of $7.08 and a two-hundred day simple moving average of $7.47. Lifeward has a one year low of $4.14 and a one year high of $35.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC lifted its stake in shares of Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after buying an additional 198,406 shares during the period. HRT Financial LP raised its stake in Lifeward by 149.7% in the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after acquiring an additional 29,423 shares during the last quarter. Jane Street Group LLC lifted its position in Lifeward by 77.3% during the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after acquiring an additional 29,927 shares during the period. Finally, Virtu Financial LLC lifted its position in Lifeward by 158.0% during the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after acquiring an additional 37,037 shares during the period. Hedge funds and other institutional investors own 26.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright reduced their price objective on shares of Lifeward from $156.00 to $54.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lifeward in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lifeward currently has an average rating of “Hold” and a consensus target price of $51.00.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.